Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Satya Therapeutics Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 distinct examiner and 1 distinct art unit. WHITE, DAWANNA SHAR-DAY is the busiest examiner, with 1 pending matter.
The concentrated record supports a focused biotechnology prosecution plan. Counsel can address the pending action through one examiner relationship and one art-unit context, without coordinating parallel examination positions. The response should connect any proposed claim language to the technical disclosure and preserve commercially relevant scope while directly resolving the stated examination issue.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837659 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | WHITE, DAWANNA SHAR-DAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837659 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18837659 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | WHITE, DAWANNA SHAR-DAY | 1627 | §102§103§112 | Non-Final OA | — | Pending | Aug 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSatya Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dawanna Shar-Day White has the most, with 1 of Satya Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
